Regeneron Widens Another Eylea Biosimilar Clash After Patent Win

Regeneron Pharmaceuticals Inc. expanded its courtroom battle over a Samsung Biologics Co. unit’s biosimilar version of Eylea, alleging in a new lawsuit that it infringes 51 patents for the eye drug, including one a West Virginia federal judge on Wednesday found Viatris Inc.’s biosimilar infringes.

Regeneron filed its heavily redacted, 83-page complaint against Samsung Bioepis Co. in the same federal court where the judge who issued the Viatris ruling was assigned to the new case. It’s seeking damages including lost profits for any infringement, and orders blocking the biosimilar for the duration of the suit and until the patents have ...